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Abstract: Thyroid-associated ophthalmopathy (TAO), or thyroid eye disease, is a complex 
inflammatory disorder of the eye that, as its name implies, is associated with thyroid disease. 
TAO can be divided into three subtypes: ocular myopathy, congestive myopathy and mixed 
congestive and myopathic ophthalmopathy. Although the precise pathophysiology of TAO 
remains unclear it is likely to reflect an autoimmune reaction involving sensitized T-cells and 
autoantibodies directed against a thyroid and orbital tissue shared antigen. One well studied 
candidate in this immune reaction is the thyroid-stimulating hormone receptor (TSH-r), expressed 
in the orbital fibroblast and pre adipocyte. In our studies of TAO, we have investigated the nature 
and significance of antibodies targeting other eye muscle and orbital connective tissue (OCT) 
antigens. Our findings suggest that autoimmunity against the eye muscle antigen calsequestrin 
and the OCT antigen collagen XIII plays a role in the pathogenesis of TAO. We propose that 
ocular myopathy and chronic eyelid retraction are due to autoimmunity against skeletal muscle 
calsequestrin in the extraocular and eyelid muscles, respectively. This may be initiated in the 
thyroid where calsequestrin expression is upregulated, possibly due to a stimulatory effect of 
TSH-r antibodies. We also propose that congestive ophthalmopathy results from a reaction 
against the TSH-r or collagen XIII in orbital fibroblast cell membranes. Further insight into the 
role of eye muscle and OCT antigens in the pathogenesis of TAO may allow for the development 
of new therapies to treat the eye disorder and reduce patient morbidity.
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Introduction
Ophthalmopathy is a common manifestation of Graves’ disease. The association between 
“poppy eyes” and goitre was described as early as 1,000 AD by the Persian physician and 
philosopher Avicenna.1 Although ophthalmopathy is most commonly seen in patients with 
Graves’ hyperthyroidism, in whom it is called Graves’ ophthalmopathy (GO).2,3 It is also 
present in a small proportion of patients with transient (subacute and silent) thyroiditis.4,5 
Mild eye changes, particularly upper eyelid retraction (UER), are present in about a third 
of patients with progressive (Hashimoto’s) thyroiditis.6 Ophthalmopathy also occurs in 
the apparent absence of thyroid autoimmunity in 10% of patients, but is presumed to be 
the same disorder, ie, an autoimmune ophthalmitis. The most appropriate name may be 
thyroid-associated ophthalmopathy (TAO), or thyroid orbitopathy. Here, we use the general 
term TAO for the spectrum of eye changes in patients with thyroid disease and GO when 
we refer to the ophthalmopathy associated with Graves’ hyperthyroidism.
The precise pathophysiologic mechanisms underlying the development of 
TAO and the explanation for its link with the thyroid are incompletely understood. Clinical Ophthalmology 2010:4 418
Lahooti et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
An understanding of these mechanisms is however essential 
due to the considerable morbidity associated with TAO7,8 
and the need for specific and safe therapies. The general 
consensus is that TAO is likely to reflect an autoimmune 
reaction during which sensitized T-cells and autoantibodies 
are directed against a thyroid and orbital tissue shared antigen 
such as the thyroid-stimulating hormone receptor (TSH-r) 
which is expressed in the thyroid, OCT and fat and, possibly, 
the extraocular muscle fiber (Box 1).9
However, recent research, mainly from the authors’ 
laboratory over the last decade, has suggested a possible 
important role for autoimmunity against other OCT and 
eye muscle antigens (Figures 1 and 2). The main antibodies 
proposed are those targeting i) the flavoprotein (Fp) subunit 
of mitochondrial succinate dehydrogenase; ii) G2s, shown 
to be a fragment of the FOX-P1 transcription factor; iii) the 
calcium binding protein calsequestrin; and iv) collagen XIII, 
a connective tissue antigen expressed in the orbital fibroblast 
cell membranes.
In this review, we attempt to summarize recent advances 
in the pathogenesis of TAO with a particular emphasis on 
a possible role of autoimmunity against calsequestrin and 
collagen XIII. In doing so, we review the TSH-r hypothesis 
and attempt to provide a unified hypothesis that explains 
all the features of TAO. We will also outline possible future 
directions for research in this developing field.
Classification of   TAO
We propose that there are three main subtypes of TAO: 
congestive ophthalmopathy, ocular myopathy and mixed 
congestive and myopathic ophthalmopathy (Table 1). 
Congestive ophthalmopathy is characterized by inflammation 
of the OCT, with relative sparing of the extra ocular muscles, 
and manifests with clinical features of eye swelling, 
LATS is the cause of Graves’ hyperthyroidism (Adams and Purvis, New Zealand)
LATS is an immunoglobulin G (lgG) antibody against TSH-r 
1956
1956
1964
1973
1986
1988
1988
1993
1998
1999
TSH-r antibody  (measured as LATS) crosses the placenta and causes neonatal
hyperthyroidism, but ophthalmopathy not observed
Graves’ ophathalmopathy is associated with higher LATS concencentrations in blood
Cytotoxic antibodies act against eye muscle cells in Graves’ ophthalmopathy
“Thyroid-associated ophthalmopathy” suggested as the best name for the eye
disorder, which occasionally occurs in patients with Hashimoto’s thyroiditis
55-, 64- and 95-kDa eye-muscle membrane proteins are recognized by serum
autoantibodies in TAO
TSH-r is expressed in retro-orbital tissue; corresponding serum autoantibodies
are postulated to be the cause of the ophthalmopathy
The 64-kDa protein is the flavoprotein subunit of mitochondrial succinate
dehydrogenase
Orbital tissue membrane antigens are recognized by sensitized T-lymphocytes
in the blood of people with TAO
2000
2000
2005
2005
Four subtypes of TAO are categorized: ocular myopathy, congestive
ophthalmopathy, mixed disease and chronic eyelid disease
G2s (a fragment of FOXP1 transcription factor), sarcalumenin and calsequestrin
are identified as eye-muscle antigens in TAO
Collagen type XIII in cell membranes of orbital fibrolasts is a target antigen in
the congestive ophthalmopathy subtype of TAO
Anticalsequestrin antibodies are sensitive and specific markers of the ocular
myopathy subtype of TAO
Note: LATS = long-acting thyroid stimulator, TSH-r =  thyroid-stimulating hormone receptor.
Box 1 Timeline of discoveries related to thyroid-associated ophthalmopathy (TAO). reproduced with the permission from Tani J, wall Jr. Autoimmunity against eye-muscle 
antigens may explain thyroid-associated ophthalmopathy. CMAJ. 2006;175(3):239.10 Copyright © 2006 Canadian Medical AssociationClinical Ophthalmology 2010:4 419
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conjunctival injection, chemosis, watery or gritty eyes and 
exophthalmos. In contrast, ocular myopathy is characterized 
by inflammation and swelling of the extraocular muscles 
and manifests as eye muscle dysfunction and diplopia and 
occasionally, painful eye movements. Although congestive 
and myopathic features can occur in isolation, mixed 
congestive and myopathic ophthalmopathy is the most 
common presentation of TAO, occurring in approximately 
60% of TAO patients.10 In patients with Hashimoto’s 
thyroiditis, UER and lag are often the only features of an 
ophthalmopathy except for and mild proptosis.6
Pathogenesis of   TAO
TSH-r hypothesis
TAO has been described as a limited multi system 
autoimmune disorder involving antigens in the OCT, eye 
muscle fiber, the lacrimal gland, and human harderian gland 
equivalent and the thyroid gland.11 The overall evidence to 
suggest that TAO is an autoimmune disorder is strong and 
no-one seriously doubts this. The uncertainty which makes 
TAO a controversial disorder is the identity of the antigens 
involved, whether the eye muscles or OCT is the primary 
target tissue in the orbit and how the ophthalmopathy is 
linked to thyroid autoimmunity. As previously mentioned, 
the general hypothesis has been that this association is due 
to cross reactivity, ie, antibodies and T cells targeting pro-
teins expressed in both the thyroid and eye. A popular theory 
is that the primary reaction may involve antibodies targeting 
the TSH-r in the OCT which leads to orbital inflamma-
tion, manifest as orbital fibroblast stimulation, collagen 
and glycosaminoglycans (GAGS) production and associ-
ated congestive eye features.12 According to this theory, 
ocular myopathy is due to secondary, ischemic, damage 
to the eye muscles following primary OCT inflammation. 
Certainly, the TSH-r is a logical candidate antigen as it is 
expressed in orbital preadipocytes and fibroblasts as well as 
the thyroid gland.12,13 Its expression in other tissues such as 
fat and connective tissue may also help to explain the devel-
opment of pretibial myxedema and thyroid acropachy in 
some patients with Graves’ disease.14,15 Although not shown 
in all reports, some studies have shown that TSH-r antibody 
levels correlate directly with clinical features of GO7 further 
implicating its role in the pathogenesis of TAO.
Although the evidence provides strong overall support 
for a role of the TSH-r in the pathogenesis of TAO, whether 
TSH-r antibodies are really linked to ophthalmopathy in 
all cases of TAO remains unclear. TSH-r antibodies cannot 
explain the development of ophthalmopathy in patients in 
whom the eye changes occur many years after the develop-
ment of Graves’ hyperthyroidism. Furthermore, the TSH-r is 
also expressed in fibroblasts and adipocytes at sites such as 
the abdominal wall which are unaffected in Graves’ disease 
patients.16 In patients with Hashimoto’s thyroiditis, eye 
changes occur in the presumed absence of TSH-r antibody 
production. Finally, newborns with thyrotoxicosis do not 
have ophthalmopathy, even when the mother has eye signs. 
These findings suggest that a specific link between thyroid 
autoimmunity/the TSH-r and ophthalmopathy has not been 
established in all situations.17
eye muscle auto antigens
Potential eye muscle antigens in TAO were first reported in 
the 1980s by Kodama et al18 and later by others.19–23 The initial 
antigens were detected according to their molecular weight 
by western blotting and the most consistently reported eye 
muscle membrane proteins recognized by serum autoanti-
bodies in TAO patients were proteins of 55 and 64 kDa.24 The 
55 kDa protein, later called G2s,25 was recognized to be a 
fragment of the FOX-P1 transcription factor {human genome 
project}. It was also demonstrated that there were in fact three 
Table 1 Thyroid associated ophthalmology (TAO) subtypes, clinical features and candidate autoantibodies 
TAO subtype Main clinical features Candidate autoantigens
Ocular myopathy Diplopia  
eOM dysfunction  
exophthalmos
Calsequestrin  
G2sa  
Flavoprotein 
Congestive ophthalmopathy  watery, gritty eyes  
Periorbital edema 
Conjunctival injection/chemosis 
exophthalmos
TSH-r  
Collagen Xiii
Mixed congestive and myopathic  
ophthalmopathy
Congestive and myopathic  
signs/symptoms
All of the above
aG2s is a fragment of the FOX-P1 transcription factor.
Abbreviations: eOM, extra ocular muscle; TSH-r, thyroid-stimulating hormone receptor.Clinical Ophthalmology 2010:4 420
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64 kDa proteins; Fp, the 1D protein and calsequestrin.26 In 
our earlier studies, using a crude preparation of calsequestrin 
prepared from rabbit heart muscle and by measuring corre-
sponding calsequestrin antibodies by western blot analysis 
we found a modest relationship between anti-calsequestrin 
antibodies and ophthalmopathy. Anti-calsequestrin anti-
bodies were detected in 40% of patients with clinically active 
TAO but only in 5% of normal subjects.27 In a separate study 
we demonstrated that anti-G2s antibodies were also associ-
ated with active ophthalmopathy in patients with Graves’ 
hyperthyroidism, being detected in 54% of patients with 
active TAO compared to 33% of those with inactive disease. 
Anti-G2s antibody detection was shown to precede the devel-
opment of congestive ophthalmopathy in 7 out of 8 patients 
and ocular myopathy in 6 out of 7 patients.28 In patients with 
Graves’ hyperthyroidism, early studies also highlighted the 
role of Fp as a potential marker of eye muscle inflammation. 
Anti-Fp antibodies were detected in 66% of patients with 
ophthalmopathy and eye muscle involvement and in 32% 
of patients with congestive ophthalmopathy.28 Fp antibody 
positivity was also shown to precede the development of 
ocular myopathy, but not congestive ophthalmopathy, in 
5 out of 6 patients.28
Although these initial studies seemed to demonstrate 
that antibodies against Fp and G2s were closely linked to 
the eye muscle component of ophthalmopathy neither are 
specific to the eye muscle and both antigens are expressed 
in tissues not normally involved in Graves’ disease.3,29 More-
over, Fp and G2s are both intracellular proteins and would 
not encounter T-cells or antibodies until the eye muscle fiber 
cell membrane had been breached. It turns out that anti-G2s 
antibodies are not specific to TAO, being detected in 5% to 
10% of healthy subjects and in a few patients with thyroid 
autoimmunity without ophthalmopathy.25,29,30 The presence 
of both antibodies have also been demonstrated in 60% of 
patients with non-specific orbital inflammation31 and anti-Fp 
antibodies in 50% of patients with ocular myasthenia gravis. 
Taking all the evidence into account, it would appear that 
antibodies against G2s and Fp are nonspecific markers of 
eye muscle damage.
roles of autoimmunity against 
calsequestrin and collagen Xiii
When Porter et al32 showed that calsequestrin was expressed 
4.8 times more in eye muscle compared to other skeletal 
muscle, thus offering an explanation for the orbital specific-
ity of skeletal muscle inflammation in Graves’ disease, we 
decided to re visit its possible role in the pathogenesis of  TAO. 
Calsequestrin seemed a good candidate as it was shown to 
be distributed throughout the cell during the myotube stage 
of differentiation, where it could be seen by antibodies and 
T-cells (Beard N, pers comm). At that time we were also 
interested in the connective tissue antigen collagen XIII 
because serum antibodies against collagen XIII were shown 
to be good markers of ophthalmopathy in patients with active 
ophthalmopathy.33
In our initial studies we reinvestigated the prevalence of 
anti-calsequestrin antibodies in a large group of patients with 
thyroid autoimmunity with and without ophthalmopathy and 
in healthy subjects.34 These studies were performed using 
enzyme-linked immunosorbent assay (ELISA) incorporating 
highly purified rabbit skeletal muscle calsequestrin which 
shares 97% homology with human calsequestrin. We dem-
onstrated that calsequestrin antibodies were good markers 
of ophthalmopathy, in particular of the ocular myopathy 
subtype of TAO in patients with Graves’ hyperthyroid-
ism, being generally negative in patients with Hashimoto’s 
thyroiditis without eye signs, multi nodular goitre and in 
healthy control subjects.34 We also demonstrated that anti-
calsequestrin antibodies correlated with the onset of ocular 
myopathy in 6 out of 11 patients with GO.34 These findings 
were important as they were the first to highlight the potential 
role of calsequestrin antibodies in the differential diagnosis 
of orbital inflammation and as markers to assess the efficacy 
of therapies for ophthalmopathy.
In light of these findings, and to further characterize 
the role of eye muscle and collagen XIII antigens in the 
pathogenesis of TAO, we conducted a study in which we 
determined the prevalence and levels of antibodies against 
calsequestrin, collagen XIII, Fp and G2s in the same study 
cohort, using ELISA. The prevalences of calsequestrin 
and collagen XIII antibodies, and to a lesser extent Fp 
antibodies, were significantly greater in patients with GO 
compared to healthy controls and in GO patients compared to 
those with Graves’ hyperthyroidism patients without oph-
thalmology, which was not the case for antibodies targeting 
G2s. Finally, positive antibody reactivity against calsequestrin 
and collagen XIII was not observed in any of the healthy 
controls, while Fp and G2s antibodies were found in 14.3% 
and 4.8% respectively, of controls.35
To further characterize the mechanism for chronic eyelid 
disease we carried out a similar study in patients with; Graves’ 
disease with UER as a dominant feature of their ophthal-
mopathy, Hashimoto’s thyroiditis with UER as an isolated 
abnormality and non-immunologic thyroid disease associated 
with UER.36 We found a generally good correlation between Clinical Ophthalmology 2010:4 421
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the prevalence of antibodies targeting calsequestrin and 
collagen XIII and the severity of UER in these patient groups. 
Calsequestrin is highly expressed in the EOM32 including, 
presumably, the levator palpebrae superioris (LPS) muscle. 
Type XIII collagen, expressed in fibroblast cell membranes, 
is also widely expressed in the adult and developing human 
eye.36 Although yet to be proven by histological analysis, 
our findings suggest that chronic UER and lag may reflect 
autoimmunity against calsequestrin and collagen XIII in the 
LPS muscle.
Ophthalmopathy in patients 
with thyroiditis
Subacute thyroiditis (SAT) and silent thyroiditis (ST) are 
the most common causes of transient thyrotoxicosis. In 
both, hyperthyroidism is the result of rapidly progres-
sive thyroid follicular cell injury and the release of large 
amounts of thyroid hormone into the systemic circulation. 
Hypothyroidism, a consequence of thyroid cell damage and 
the subsequent depletion of thyroid hormone stores, often 
follows. SAT is caused by viral induced inflammation of 
the thyroid gland. Sporadic ST, on the other hand, appears 
to be an autoimmune disease. There have been reports of the 
development of TSH-r positive Graves’ hyperthyroidism and 
ophthalmopathy following SAT.37,38 However, Amato et al39 
recently reported the case of a Caucasian male who developed 
euthyroid Graves’ disease after proven SAT in the absence of 
TSH-r antibodies but with detectable eye muscle antibodies. 
This prompted us to study the prevalence of eye and eyelid 
signs and positive eye muscle and collagen XIII antibody tests 
in 11 patients with transient thyroiditis (5 with SAT and 6 with 
ST), 11 patients with Hashimoto’s thyroiditis as chronic 
thyroiditis controls and in 12 age and sex-matched healthy 
controls.5 In summary, 5 patients with transient thyroiditis 
and 5 with Hashimoto’s thyroiditis were found, at first visit 
or on follow-up, to have developed ophthalmopathy. TSH-r 
antibodies were found in only one patient who developed 
Graves’ hyperthyroidism following an episode of ST. 
One or more eye muscle or collagen XIII antibodies were 
detected in 7 patients with transient thyroiditis and in 7 with 
Hashimoto’s thyroiditis, and antibody levels correlated gen-
erally with eye signs. Calsequestrin and Fp antibodies were 
the most frequently detected and collagen XIII antibodies 
were detected in only two patients with ST and one patient 
Extraocular fibre
Orbital fibroblast
Calsequestrin
Antibodies
Flavoprotein
Mitochondrion Sarcolemmal
membrane
Putative
cell-membrane
antigen
T-cell receptor
and MHC protein
G2s (FOXP1)
T-lymphocyte
Antibodies
Nuclei
Endoplasmic
reticulum
Type XIII Collagen
TSH-r-like protein
Figure 1 Eye muscle and orbital fibroblast autoantigens recognized by T lymphocytes or antibodies in thyroid-associated ophthalmopathy (TAO). Our working hypothesis 
is that the ocular myopathy subtype of   TAO is initiated by   T lymphocyte-mediated targeting of calsequestrin or a yet unidentified eye muscle cell membrane antigen. Serum 
antibodies against flavoprotein, G2s and sarcalumenin are likely to be secondary to release of the proteins following muscle fiber necrosis. Chronic eyelid disease, which is a 
feature of TAO or a dominant sign in patients with Hashimoto’s thyroiditis, may be the result of  T lymphocyte-mediated targeting of calsequestrin in the upper eyelid leva-
tor palpebrae superioris muscle.   The congestive ophthalmopathy subtype of  TAO is likely to result from a reaction against the  TSH-r or collagen XIII in the fibroblast cell 
membranes, which leads to fibroblast stimulation and excess production of collagen and glycosaminoglycans. The different reactions shown in the figure may occur alone 
or in combination. reproduced with the permission from Tani J, wall Jr. Autoimmunity against eye-muscle antigens may explain thyroid-associated ophthalmopathy. CMAJ. 
2006;175(3):239.10 Copyright © 2006 Canadian Medical Association
Abbreviations: MHC, major histocompatibility complex;   TSH-r, thyroid-stimulating hormone receptor.Clinical Ophthalmology 2010:4 422
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with Hashimoto’s thyroiditis.5 These findings suggest that 
ophthalmopathy associated with destructive thyroiditis is 
mainly an eye muscle disorder.
To further study the prevalence and phenotype of oph-
thalmopathy in patient with Hashimoto’s thyroiditis, we 
have recently studied 91 recently diagnosed patients with 
Hashimoto’s thyroiditis for eye and upper eyelid signs 
and correlated these with calsequestrin and collagen XIII 
antibodies.6 We showed that the prevalence of eye signs in 
patients with Hashimoto’s thyroiditis was much greater than 
previously thought, being present in 34% of the patients. 
This observation again raises questions about the role of the 
TSH-r in the pathogenesis of ophthalmopathy. Because TSH-r 
antibodies are expected to be negative in the majority of 
patients with Hashimoto’s thyroiditis, their ophthalmopathy 
cannot be explained by autoimmunity against the “TSH-r in 
the LPS muscle”.
T lymphocyte reactivity against  
orbital antigens
Recent studies addressing the putative role of cell-mediated 
immunity in TAO have also generated important insights into 
the pathogenesis of this disorder.40 Immunohistological analysis 
has shown that TAO is characterized by the infiltration of 
EOM and OCT by mononuclear cells consisting predominantly 
of T-cells.41–43 We investigated the role of peripheral blood 
T cell mediated reactivity against calsequestrin, Fp and G2s in 
22 patients with GO, 9 patients with Graves’ hyperthyroid-
ism without ophthalmopathy and in 16 age and sex matched 
healthy controls, using a standard lymphocyte proliferation 
assay.44 The prevalence of positive lymphocyte reactivity 
to calsequestrin was 58% in all patients with GO, 67% in 
those with active disease and in 33% of patients with Graves’ 
hyperthyroidism without ophthalmopathy. Positive lympho-
cyte reactivity to Fp and G2s however was not significantly 
different between patients with GO, Graves’ hyperthyroidism 
without ophthalmopathy or healthy controls.44
The specific mechanisms responsible for T cell-migration 
into orbital tissues and autoantigen recognition and the roles 
of costimulatory signal activation and cytokines, are poorly 
understood. We postulate that the eye muscle component of 
TAO is initiated by T-cells targeting some cell membrane anti-
gen, possibly calsequestrin. Thereafter, these recruited T-cells 
may release various cytokines that stimulate retro-orbital fibro-
blasts to proliferate and secrete GAGs, leading to congestive 
ophthalmopathy and orbital fibrosis (Figures 1 and 2).
risk factors for ophthalmopathy
The phenotypic variation of eye signs in patients with TAO 
suggests that complex interactions between endogenous 
Adipogenesis
GAG synthesis
TSH-R
IGF-1R Autoantibodies
CD40/CD40 Ligand
MHC/TCR
ICAM-1/LFA-1
CYTOKINES
OF L
Figure 2 Orbital fibroblast activation in thyroid-associated ophthalmopathy. The main features of Graves’ ophthalmopathy include the enlargement of eye muscles and the expan-
sion of the orbital fatty connective tissues.  These changes result from accumulation of glycosaminoglycans (GAGs) and edema within these tissues and de novo adipogenesis.   The 
orbital fibroblast (OF) appears to be the major effector cell in GO influencing both processes. In the active stage of disease, OF are capable of producing large amounts of 
GAGs following (i) stimulation by cytokines (especially Th-1 cytokines), (ii) activation of CD40 by CD40 ligand and (iii) activation of insulin growth factor receptor (iGF-1r) by 
autoantibodies.   A subset of OF, the preadipocytes, are capable of differentiating into mature adipocytes following appropriate stimulation by cytokines (iL-6) and activation of 
thyroid-stimulating hormone receptor (TSH-r). in addition, OF have been shown to display the immunoregulatory molecules major histocompatibility complex MHC class ii 
(HLA-DR) and intercellular adhesion molecule-1 (ICAM-1), and also are capable of secreting chemokines and cytokines which stimulate the infiltration of activated T cells into 
areas of inflammation. In the ‘burn-out’ stage of ophthalmopathy, OF participate in tissue fibrosis. Reproduced with permission from Bednarczuk T, Gopinath B, Ploski R,   Wall 
Jr. Susceptibility genes in Graves’ ophthalmopathy: searching for a needle in a haystack? Clin Endocrinol (Oxf ). 2007; 67(1):3–19.45 Copyright © 2007 wiley Blackwell.
Abbreviations: LFA, lymphocyte function-associated antigen; MHC, major histocompatibility complex.Clinical Ophthalmology 2010:4 423
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(genetic factors, increasing age, male sex) and exogenous 
(cigarette smoking, hyperthyroidism and hypothyroidism, 
radioiodine treatment) factors may influence the develop-
ment and severity of ophthalmopathy.45 Smoking appears to 
be the greatest risk factor for ophthalmopathy46,47 while the 
role of genetic factors in its development remains unclear.45 
Recent work has focused on identifying genetic alterations 
associated with GO through small scale case-controlled asso-
ciation studies with candidate genes. Several susceptibility 
loci in GO have now been proposed which include the human 
leucocyte antigen (HLA, 6p21.3), cytotoxic T-lymphocyte 
antigen-4 (CTLA-4, 2q33), tumor necrosis factor (TNF, 
6p21.3), interferon-γ (IFN-γ, 12q14), intracellular adhesion 
molecule-1 (ICAM-1, 19p13), and the thyroid stimulating 
hormone receptor gene (TSH-R, 14q31). The results of 
association studies published so far however are inconclusive 
because the vast majority of them are underpowered and 
poorly characterized.45
Microarray expression studies
Recently, we extracted total RNA prepared from thyroid 
tissue of patients with Graves’ hyperthyroidism with (GO) 
and without (GH) ophthalmopathy and tested it for expres-
sion across 20,589 genes determined using micro array 
gene expression analysis.48 We were looking for differences 
in gene expression between these two patient groups which 
might provide insight into the early thyroid events that lead 
to the development of ophthalmopathy. Of the 20,589 genes 
surveyed, 296 genes were identified to be differentially 
expressed between patients with GO and GH. Of these 
genes, the skeletal muscle calsequestrin gene, CASQ1, was 
up-regulated 4.1-fold in GO vs GH, although this was not 
statistically significant. Surprisingly, the cardiac calseques-
trin gene, CASQ2, was the most highly up-regulated gene, 
2.2-fold, in thyroid tissue from GO vs GH. The orbital 
antigen, Fp, was also found to be significantly up-regulated, 
1.4-fold, while genes encoding collagen XIII, FOXP1/G2s, 
thyroglobulin, thyroid peroxidise and the TSH-r, were not 
differentially expressed.48
Skeletal muscle calsequestrin and cardiac muscle 
calsequestrin are closely related proteins that share 68.4% 
homology. Interestingly, like skeletal muscle calsequestrin, 
cardiac muscle calsequestrin is also expressed more in the 
eye muscle than other skeletal muscle, 2.7-fold.49 The find-
ing that the CASQ2 gene was the most highly upregulated 
gene in thyroid tissue from patients with GO is unlikely to 
be a chance finding. Although the CASQ1 gene was not 
significantly up-regulated in GO patients it is possible that 
one or more of the patients in GH patients “without eye 
signs” manifested subclinical ophthalmopathy at the time 
of thyroidectomy. It is clear that calsequestrin genes are not 
supposed to be expressed in the thyroid gland and their up-
regulation in the thyroid of patients with ophthalmopathy 
provides further support for a role of autoimmunity against 
calsequestrin in its pathogenesis. The next step would be 
immune sensitization to calsequestrin and cross-reactivity 
against the same protein in eye and eyelid muscles.
Unifying hypothesis
Most workers and readers accept the TSH-r hypothesis as 
being fact.50 However, recent developments have suggested 
a possible role for autoimmunity against other orbital anti-
gens in the pathogenesis of TAO, as described above, and 
this deserves to be taken seriously. We postulate that while 
antibodies directed against the TSH-r may be the initiating 
event that leads to orbital inflammation, collagen XIII is also 
good candidate antigen in the congestive subtype of  TAO as 
it has been shown to be expressed in the plasma membrane of 
orbital fibroblasts, and thus accessible to the immune system. 
Antibody and T lymphocyte reactivity against calseques-
trin, or some other eye muscle cell membrane antigen, may 
separately and independently lead to eye and eyelid muscle 
inflammation and damage, manifest as diplopia and UER 
(Figure 1). It seems less likely that autoimmunity against the 
TSH-r leads to secondary eye muscle damage particularly 
as ocular myopathy can occur as an isolated abnormality 
occasionally in patients with no associated thyroid disease. 
Support for the theory of primary autoimmunity involving 
the eye muscles can be demonstrated by electron microscope 
examination in GO patients with relatively recent onset dis-
ease showing muscle fiber damage in the absence of OCT 
inflammation.14
Future directions
Although our studies have raised the possibility that 
autoimmunity against calsequestrin and collagen XIII may 
play a role in the pathogenesis of TAO this is not proven. 
Larger prospective studies of patients with newly diagnosed 
TAO in which serum antibody levels and parameters of 
blood and, better, orbital T lymphocyte reactivity against 
the two antigens are correlated with clinical features of TAO 
and accurate measurements of extra ocular muscle volumes 
from orbital imaging, are needed. Patients with other skeletal 
muscle inflammatory and autoimmune disorders should be 
studied to confirm disease specificity of the serum antibodies. 
Other possible avenues for future research include elucidating Clinical Ophthalmology 2010:4 424
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the mechanisms regulating T lymphocyte migration into 
retroorbital tissue, there activation by autoantigens and the 
role of cytokines and co stimulatory signals. It is also impor-
tant to attempt to develop an animal model in which we can 
further investigate the nature and significance of calsequestrin 
and collagen XIII in the pathogenesis of TAO.
Finally, the role of putative genetic factors in the devel-
opment of ophthalmopathy remain unclear. So far, case-
controlled studies with candidate genes have identified 
several susceptibility loci, however important candidate genes 
including those encoding orbital autoantigens and genes 
involved in GAGs synthesis remain to be studied. Through 
further association studies these candidate genes should 
be explored in a prospective multicenter study involving a 
large number of patients with well defined thyroid disease 
with and without ophthalmopathy. Whole genome analysis 
for polymorphisms of the calsequestrin and collagen XIII 
genes may also provide information about new genes and 
their proteins involved in the pathogenesis of TAO which 
could be considered as targets for therapy.
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